Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F11 | P03951 | 20/20 | 0.86 |
| ▸ | F7 | P08709 | 20/20 | 0.86 |
| ▸ | F10 | P00742 | 19/20 | 0.86 |
| ▸ | KLKB1 | P03952 | 2/20 | 0.79 |
| ▸ | F2 | P00734 | 1/20 | 0.79 |
| ▸ | PLG | P00747 | 1/20 | 0.79 |
| ▸ | PLAU | P00749 | 1/20 | 0.79 |
| ▸ | PLAT | P00750 | 1/20 | 0.79 |
| ▸ | PROC | P04070 | 1/20 | 0.79 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.79 |
| ▸ | PRSS2 | P07478 | 1/20 | 0.79 |
| ▸ | PRSS3 | P35030 | 1/20 | 0.79 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5846336 | 0.99 | F11 (0.85) | F11F7F10KLKB1F2 | |
| SCHEMBL5846505 | 0.97 | F11 (0.82) | F11F7F10KLKB1F2 | |
| SCHEMBL4733025 | 0.97 | F11 (0.82) | F11F7F10KLKB1F2 | |
| SCHEMBL4737987 | 0.96 | F11 (0.88) | F11F7F10KLKB1F2 | |
| SCHEMBL4736228 | 0.96 | F11 (0.84) | F11F7F10KLKB1F2 | |
| SCHEMBL4736432 | 0.96 | F11 (0.89) | F11F7F10KLKB1F2 | |
| SCHEMBL5845808 | 0.95 | F11 (0.79) | F11F7F10KLKB1F2 | |
| SCHEMBL4735234 | 0.94 | F11 (0.83) | F11F7F10KLKB1F2 | |
| SCHEMBL5846870 | 0.94 | F11 (0.88) | F11F7F10KLKB1F2 | |
| SCHEMBL3549704 | 0.93 | F11 (1.00) | F11F7F10KLKB1F2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7138412-B2 | Tetrahydroquinoline derivatives useful as serine protease inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2006-11-21 | — | — | US | claimed |
| US-20040235847-A1 | Tetrahydroquinoline derivatives useful as serine protease inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2004-11-25 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040235847-A1 | Tetrahydroquinoline derivatives useful as serine protease inhibitors | TFPI, F2, TFPI2 | F11 7/4885F7 23/4885F10 18/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.